Netherlands· NL-18a432ddad08

Cayston 75 mg, poeder voor verneveloplossing

A aztreonam product containing aztreonam, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 16 of our 19 countries.

ATC J01DF01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about aztreonamAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Aztreonam is registered in 16 of 19 countries.

Countries holding a registration under ATC J01DF01 (aztreonam), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search aztreonam products by name

Aztreonam · ATC J01DF01

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Spainprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aztreonam costs, country by country.

Normalised to the WHO defined daily dose (0.225 g), the median price runs from $4.80 in Spain to $107.66 in Switzerland — a ×22 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Aztreonam · price per daily dose (0.225 g)

USD · FX 28 Sept 2026

CH Switzerland$107.66
ES Spain$4.80

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AZTREONAM
Manufacturer: Gilead Sciences Ireland UC
Country: Netherlands (NL)
ATC code: J01DF01
ATC class: Aztreonam
Defined daily dose: 0.225 g, Inhal
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/09/543

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

40 interactions on record for aztreonam.

Graded by severity as the source publishes them — 10 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check aztreonam against other medicines How interaction checks work

Aztreonam · interactions on record

40 records

10 moderate
30 info

Most severe, free to view

Sodium picosulfateA06AB08moderate
DicoumarolB01AA01moderate
WarfarinB01AA03moderate
Levonorgestrel and ethinylestradiolG03AA07moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aztreonam in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aztreonam products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

Austria · Azactam
Belgium · Azactam
Spain · Azactam
Finland · Azactam
France · Azactam
United Kingdom (Northern Ireland) · Aztreonam Kent Pharma Uk, Aztreonam Kent Pharma Uk Ltd
Ireland · Azactam
Iceland · Cayston
Liechtenstein · Cayston
Luxembourg · Azactam
Norway · Azactam, Cayston
Portugal · Azactam
Romania · Azactam
Sweden · Azactam

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f9bfad21-a018-446b-8752-409ce0dab98f
GET /v1/drugs/f9bfad21-a018-446b-8752-409ce0dab98f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor verneveloplossing",
  "route": "Inhalatie",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cayston-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Aztreonam",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp102159",
  "excipients": [
    "LYSINE (L-) 1-WATER",
    "NATRIUMCHLORIDE",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "AZTREONAM"
  ],
  "leaflet_url": null,
  "authorised_at": "2009/09/21",
  "procedure_number": "EMEA/H/C/000996",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/09/543",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about aztreonam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console